cancer-therapy-and-biomarkers-2016_tracks-abstracts

19 / 36

Volume 2, Issue 3(Suppl) Oncol Cancer Case Rep
ISSN: 2471-8556 an open access journal
Page 46
Notes:
Cancer Therapy & Biomarkers 2016
December 05-07, 2016
conferenceseries.com
CANCER THERAPY,
BIOMARKERS & CLINICAL RESEARCH
15th World Congress on
December 05-07, 2016 Philadelphia, USA
Anaemia in cancer patients undergoing radiotherapy and chemotherapy in national hospital
Abuja, Nigeria
Chinedu S. Aruah,1 Oyesegun r,2 Oche Ogbe,3 Igbinoba F, 4 Okwor Vitalis,5 Abalu6, Madukwe J7 and Onyedika Okoye8
National Hospital Abuja, Abuja 1,2,3,4,6,7,8
University of Nigeria Teaching Hospital, Enugu5
Introduction: Many cancer patients present with anaemia prior to radiotherapy and chemotherapy or may experience anae-
mia /worsening of anaemia at some point during treatment.
Aims and Objectives: The aim of the study was impact of anaemia in cancer patients undergoing Radiotherapy and Chemo-
therapy.
Methodology: 201 cancer patients of both sexes with histopathologically confirmed malignancies (solid cancers). Patient’s
pre-treatment Hb was taken. Patients were distributed into Radiotherapy, Chemotherapy and Chemoradiation. Their Hb were
measured once every 2 weeks. The blood film pictures of the patients were examined. The whole process was terminated after
3 consecutive Hb reading or after week 6. Anaemia was classified into:
Less than 10g/dl - Severe anaemia
10 - 10.9g/dl - moderate anaemia
11 - 12 g/dl - mild anaemia
12 g/dl and above - no anaemia.
Results and Analysis: Out of 201 cancer patients, 86.1% were female and 13.9% were male. Age range, 25 - 75 years, 100 pa-
tients were on Chemotherapy, 63 patients on Radiotherapy and 38 patients on Chemoradiation. The prevalence in anaemia in
cancer patients undergoing radiotherapy and chemotherapy was found to be 63% as shown by blood film picture (i.e average of
72%, 42.9% and 73.7%). At the end of therapy, 62% (100) patients on Chemotherapy and 55.6% (63) patients on Radiotherapy
had their Hb level between 11-12g/dl, 39.5% (38) cancer patients on Chemoradiation arm had Hb value of 10-10.9 g/dl. At P-
value > 0.05, there was no statistical significance on distribution of mean Hb, standard deviation based on sex and treatment
type.
Conclusion: Prevalence of anaemia in the study group was found to be 63% while 37% had adequate haemoglobin (Hb) after
the therapy as reflected in the blood film picture. At 95% confidence interval, Chemotherapy had greatest impact on Hb lev-
el during therapy. Thus Chemotherapy; 9.60-10.62g/dl, Radiotherapy; 11.52-12.1 3g/dl, Chemoradiation therapy; 10.98-11.3
6gIdl.
Chinedu S. Aruah et al., Oncol Cancer Case Rep 2016,2:3(Suppl)